Research Spotlight: Shining light on nuclear-targeted therapy using gold nanostar constructs

Therapeutic Delivery

Volumn 3, Issue 11, 2012, Pages 1263-1267

  Dam, Duncan Hieu M ^a   Culver, Kayla S B ^b   Sisco, Patrick N ^a   Odom, Teri W ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; GOLD NANOPARTICLE; GOLD NANOSTAR; NUCLEOLIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GOLD; METAL NANOPARTICLE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL INTERACTION; CELL NUCLEUS MEMBRANE; CELL TYPE; CELL VIABILITY; COMPOSITE MATERIAL; DNA REPAIR; DRUG TRANSPORT; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; NUCLEAR TARGETED CANCER THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY; CELL NUCLEUS; DRUG DELIVERY SYSTEM; LIGHT; METABOLISM;

ANTINEOPLASTIC AGENTS; CELL NUCLEUS; DRUG DELIVERY SYSTEMS; GOLD; HUMANS; LIGHT; METAL NANOPARTICLES;

EID: 84870173511     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.107     Document Type: Article

References (31)

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007). (Pubitemid 350223348)
2. Kim BY, Rutka JT, Chan WC. Nanomedicine. New Engl. J. Med. 363, 2434-2443 (2010).
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157 (2005). (Pubitemid 41486396)
4. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-1146 (2005). (Pubitemid 41486395)
5. McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1998). (Pubitemid 28363048)
6. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 59, 2020-2020 (1999).
7. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447-464 (2010).
8. Hockenbery DM. Targeting mitochondria for cancer therapy. Environ. Mol. Mutagen. 51, 476-489 (2010).
9. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99-163 (2007). (Pubitemid 46209992)
10. Schwartz GK, Shah MA. Targeting the cell cycle: A new approach to cancer therapy. J. Clin. Oncol. 23, 9408-9421 (2005).
11. Faustino RS, Nelson TJ, Terzic A, Perez-Terzic C. Nuclear transport: target for therapy. Clin. Pharmacol. Ther. 81, 880-886 (2007). (Pubitemid 46788292)
12. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185-198 (2012).
13. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AKR, Han MS, Mirkin CA. Oligonucleotide-modifed gold nanoparticles for intracellular gene regulation. Science 312, 1027-1030 (2006).
14. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14, 1310-1316 (2008). (Pubitemid 351413909)
15. Austin LA, Kang B, Yen CW, El-Sayed MA. Nuclear targeted silver nanospheres perturb the cancer cell cycle differently than those of nanogold. Bioconj. Chem. 22, 2324-2331 (2011).
16. Kang B, Mackey MA, El-Sayed MA. Nuclear targeting of gold nanoparticles in cancer cells induces DNA damage, causing cytokinesis arrest and apoptosis. J. Am. Chem. Soc. 132, 1517-1519 (2010).
17. Pan LM, He Q, Liu J et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J. Am. Chem. Soc. 134, 5722-5725 (2012).
18. de la Fuente JM, Berry CC. Tat peptide as an effcient molecule to translocate gold nanoparticles into the cell nucleus. Bioconj. Chem. 16, 1176-1180 (2005). (Pubitemid 41368118)
19. Ming X, Feng L. Targeted delivery of a splice-switching oligonucleotide by cationic polyplexes of RGD-oligonucleotide conjugate. Mol. Pharm. 9, 1502-1510 (2012).
20. Prabha S, Labhasetwar V. Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol. Pharm. 1, 211-219 (2004).
21. Symens N, Walczak R, Demeester J, Mattaj I, De Smedt SC, Remaut K. Nuclear inclusion of nontargeted and chromatin-targeted polystyrene beads and plasmid DNA containing nanoparticles. Mol. Pharm. 8, 1757-1766 (2011).
22. Zhou ZX, Shen Y, Tang J et al. Linear polyethyleneimine-based charge-reversal nanoparticles for nuclear-targeted drug delivery. J. Mater. Chem. 21, 19114-19123 (2011).
23. Stuart RK, Stockerl-Goldstein K, Cooper M et al. Randomized Phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML). J. Clin. Oncol. 27, 15 s (2009).
24. Miller DM, Taft BS, Kloecker GH, Bates PJ, Trent JO, Miller DM. Extended Phase I study of AS1411 in renal and non-small cell lung cancers. Ann. Oncol. 17, 147-148 (2006).
25. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 86, 151-164 (2009).
26. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 163, 871-878 (2003). (Pubitemid 37517893)
27. Soundararajan S, Wang L, Sridharan V et al. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol. Pharmacol. 76, 984-991 (2009).
28. Dam DH, Lee JH, Sisco PN et al. Direct observation of nanoparticle-cancer cell nucleus interactions. ACS Nano. 6, 3318-3326 (2012).
29. Sibbett W, Lagatsky AA, Brown CTA. The development and application of femtosecond laser systems. Opt. Express 20, 6989-7001 (2012).
30. Barhoumi A, Huschka R, Bardhan R, Knight MW, Halas NJ. Light-induced release of DNA from plasmon-resonant nanoparticles: towards light-controlled gene therapy. Chem. Phys. Lett. 482, 171-179 (2009).
31. Huschka R, Neumann O, Barhoumi A, Halas NJ. Visualizing light-triggered release of molecules inside living cells. Nano. Lett. 10, 4117-4122 (2010).